Former U.S. Congresswoman Tulsi Gabbard recently stated that the United States has funded over 120 biological research laboratories operating in more than 30 countries globally. Gabbard announced the release of what she described as "never-before-seen intelligence," asserting these facilities are linked to programs aimed at pathogen research, surveillance, and disease diagnostics.

Gabbard, a former Democratic presidential candidate, articulated her concerns regarding the oversight and potential implications of these U.S.-funded facilities. Her statements emphasized that while these programs are often presented as initiatives for public health and biosecurity, their extensive network raises questions about accountability and the management of high-risk biological agents. She highlighted the stated objectives of these programs, which typically include enhancing global health security, countering biological threats, and preventing the proliferation of dangerous pathogens.

According to Gabbard's interpretation of the intelligence, the U.S. Department of Defense, specifically through agencies like the Defense Threat Reduction Agency (DTRA), has provided significant funding for these laboratories. The programs reportedly encompass a range of activities, from monitoring infectious diseases to conducting research on highly pathogenic organisms. Gabbard's primary concern centers on the potential for accidental release of dangerous pathogens from these facilities and the lack of comprehensive public knowledge or congressional oversight regarding their operations and safety protocols.

Key details from her announcement include:

  • Scope: Over 120 biological research facilities identified.
  • Geographic Reach: Located in more than 30 countries worldwide.
  • Funding Source: Allegedly linked to U.S. government departments, notably the Department of Defense.
  • Primary Activities: Pathogen surveillance, diagnostics, and research related to biological threats.
  • Expressed Concerns: Potential for accidental pathogen release, insufficient transparency, and national security implications.

Gabbard's public statements call for increased transparency from the U.S. government regarding the nature and full scope of these international biological research programs. She advocated for greater public scrutiny and accountability mechanisms to ensure that these facilities do not pose unforeseen risks to global public health or U.S. national security interests. Her remarks suggest a need for a re-evaluation of current policies and a more robust framework for managing biological research conducted with U.S. funding abroad. The release of this information prompts questions regarding the ongoing dialogue surrounding international biosecurity efforts and the role of various nations in these initiatives.